✦ LIBER ✦

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer : A phase 2 trial of the Eastern Cooperative Oncology Group

✍ Scribed by Athanassios Argiris; Ashley Buchanan; Bruce Brockstein; Jill Kolesar; Musie Ghebremichael; Michael Pins; Kristine Hahn; Rita Axelrod; Arlene Forastiere

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 157 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24528

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors and long-term survivo

Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck : An analysis of two Eastern Cooperative Oncology Group randomized trials

✍ Athanassios Argiris; Yi Li; Arlene Forastiere 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

Phase II trial of irinotecan plus cispla

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

✍ Jill Gilbert; Anthony Cmelak; Yu Shyr; James Netterville; Brian B. Burkey; Rober 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr

Phase 2 trial of sorafenib in patients w

Phase 2 trial of sorafenib in patients with advanced urothelial cancer : A Trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J. R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Phase II trial of gemcitabine and doceta

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Judith Manola; Daniel J. Schneider; John F. Schwerkoske; Christo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract ## BACKGROUND Gemcitabine and docetaxel are active agents in advanced urothelial carcinoma. A Phase II trial of this combination was performed to determine the activity and toxicity of these agents in a multiinstitutional setting in patients previously treated with one prior chemothera

Phase 2 trial of pemetrexed disodium and

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802) : A trial of the Eastern Cooperative Oncology Group

✍ Robert Dreicer; Hailun Li; Matthew M. Cooney; George Wilding; Bruce J. Roth 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## Abstract ## BACKGROUND. There is a need to identify active new regimens in patients with advanced urothelial cancer. Pemetrexed and gemcitabine are active agents in advanced urothelial cancer. A phase 2 trial of the combination of these 2 agents was performed in patients with advanced urothelia